Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.
Article Details
- CitationCopy to clipboard
Heim R, Lucas S, Grombein CM, Ries C, Schewe KE, Negri M, Muller-Vieira U, Birk B, Hartmann RW
Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.
J Med Chem. 2008 Aug 28;51(16):5064-74. doi: 10.1021/jm800377h. Epub 2008 Aug 1.
- PubMed ID
- 18672861 [ View in PubMed]
- Abstract
Recently, we reported on the development of potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. A major drawback of these nonsteroidal compounds was a strong inhibition of the hepatic drug-metabolizing enzyme CYP1A2. In the present study, we examined the influence of substituents in the heterocycle of lead structures with a naphthalene molecular scaffold to overcome this unwanted side effect. With respect to CYP11B2 inhibition, some substituents induced a dramatic increase in inhibitory potency. The methoxyalkyl derivatives 22 and 26 are the most potent CYP11B2 inhibitors up to now (IC50 = 0.2 nM). Most compounds also clearly discriminated between CYP11B2 and CYP11B1, and the CYP1A2 potency significantly decreased in some cases (e.g., isoquinoline derivative 30 displayed only 6% CYP1A2 inhibition at 2 microM concentration). Furthermore, isoquinoline derivative 28 proved to be capable of passing the gastrointestinal tract and reached the general circulation after peroral administration to male Wistar rats.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Quinidine Cytochrome P450 2D6 IC 50 (nM) 14 N/A N/A Details Sulfaphenazole Cytochrome P450 2C9 IC 50 (nM) 318 N/A N/A Details Tranylcypromine Cytochrome P450 2C19 IC 50 (nM) 5950 N/A N/A Details